サウスダコタにおける転移性癌の臨床試験
サウスダコタ内の拠点で、転移性癌に関する10件の研究が参加者を募集しています。
サウスダコタ内の都市
公式研究テキスト（英語）
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Avera Cancer Institute Research, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07562152Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第2相
全年齢 · 全性別 · 2026/10/05更新 · NCT05564377A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Avera Medical Group, Sioux Falls
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Avera Cancer Institute- Aberdeen, Aberdeen
- Avera Cancer Institute- Mitchell, Mitchell
- Avera Cancer Institute- Pierre, Pierre
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222800A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Avera Cancer Institute- Research, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sanford Cancer Center, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Sioux Falls
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/08更新 · NCT07647328A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
- Avera Cancer Institute, Sioux Falls
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06803680Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Sioux Falls
- Research Site, Sioux Falls
被験者募集中第3相
18歳以上 · 女性 · 2026/07/29更新 · NCT07044336Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Sanford Health, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/18更新 · NCT06757634ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。